Benitec Biopharma (BNTC) Net Income towards Common Stockholders (2019 - 2025)

Benitec Biopharma (BNTC) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$11.8 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 23.92% year-over-year to -$11.8 million; the trailing twelve-month figure through Dec 2025 stood at -$44.1 million (down 86.82% YoY), and the FY2025 full-year result was -$37.9 million, down 69.5% from the prior year.
• Net Income towards Common Stockholders fell to -$11.8 million in Q4 2025, from -$9.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$3.6 million in Q1 2022 to a low of -$22.7 million in Q2 2022.
• A 5-year average of -$8.0 million and a median of -$6.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders jumped 74.98% in 2021 and sank 460.98% in 2022, its largest moves.
• Tracing BNTC's Net Income towards Common Stockholders over 5 years: stood at -$5.0 million in 2021, then slipped by 27.07% to -$6.3 million in 2022, then declined by 7.27% to -$6.8 million in 2023, then tumbled by 40.51% to -$9.6 million in 2024, then retreated by 23.92% to -$11.8 million in 2025.
• Business Quant data shows BNTC's Net Income towards Common Stockholders at -$11.8 million in Q4 2025, -$9.0 million in Q3 2025, and -$8.8 million in Q2 2025.